Latest Capital Raises News

Cambium Bio has raised A$2.12 million through a fully subscribed placement led by Taiwanese institutional investor Da Jyun Capital, supporting the initiation of pivotal Phase 3 trials for its lead ophthalmology candidate.

Citigold Corporation Limited reports steady progress in exploration and mine design at its Charters Towers Gold Project, while actively pursuing funding partnerships to restart operations.

Memphasys Limited has submitted its Felix™ sperm separation system for CE Mark approval, targeting Europe’s $5 billion IVF market, while expanding direct sales in Japan and validating its RoXsta™ oxidative stress diagnostic platform.

Octava Minerals has successfully completed the initial phase of its $1.5 million capital raise, positioning the company to advance exploration and due diligence at its promising Federation Copper-Zinc-Silver Project.

Prodigy Gold has successfully raised over $7 million through a combined entitlement offer and placement, with Plutus Prospecting increasing its voting power to 19.9%. The funds will fuel exploration and development in the prolific Tanami Gold Province.

Gladiator Resources reported promising uranium and rare metal findings at its Tanzanian projects while initiating legal action over alleged defamation, all against a backdrop of cautious cash management.

Uvre Limited has secured a transformative portfolio of New Zealand gold projects, including the high-grade Waitekauri asset, backed by a $4 million capital raise and new board appointments. The company is gearing up for its maiden drilling campaign this September.

Orion Minerals reported significant cash outflows in its June 2025 quarter, with liquidity stretched and financing facilities nearly maxed out. The company is pursuing a $5.8 million capital raising to support ongoing operations following recent feasibility study completions.

Orion Minerals is advancing its Prieska Copper Zinc Mine towards production, targeting first concentrate by Christmas 2026, supported by a recent $5.8 million capital raise and ongoing project optimisation.

Alterity Therapeutics has secured U.S. FDA Fast Track designation for its drug ATH434 targeting Multiple System Atrophy, supported by promising Phase 2 clinical trial data showing slowed disease progression and a solid safety profile.

Codeifai Limited has raised $2.35 million through a share placement to fund key acquisitions and expand its footprint in quantum computing and AI. The move signals a strategic push towards U.S. market engagement and commercialisation of cutting-edge technology.

Latrobe Magnesium secures EPA licence extension and prepares to start magnesium oxide production in August, while pursuing a significant legal counterclaim and advancing commercial plant plans.